Stockscreener 앱 받기
3.82
2.69%
0.10
시간 외 거래:
3.82
Aardvark Therapeutics Inc 주식(AARD)의 최신 뉴스
Aardvark Therapeutics Inc. (AARD) Gains 7% as Stock Approaches Resistance LevelRisk Reward Setups - newsline.com
Aardvark Therapeutics Implements Executive Retention Bonus Agreements - TipRanks
Executive retention bonuses outlined at Aardvark Therapeutics (NASDAQ: AARD) - Stock Titan
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc.AARD - PR Newswire
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aardvark Therapeutics, Inc.AARD - FinancialContent
Aardvark Therapeutics Insiders Lose Out As Stock Sinks To US$3.59 - simplywall.st
AARD Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Risk Report - newsline.com
Aardvark Therapeutics (AARD) Slips 2.45% as Stock Tests Key Support at $3.41Elliott Wave Entry - newsline.com
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial - Stocktwits
Aardvark Therapeutics (AARD) Declines Over 4% as Stock Tests Key Support LevelsVolatility Skew - newsline.com
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid - GlobeNewswire
AARD Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue StageGAAP Earnings Report - The Legal Advocate
AARD Q1 2026 Earnings: EPS Misses Estimates but Stock Rises on Pipeline ProgressEPS Revision Trend - The Legal Advocate
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS - Moomoo
Several Insiders Invested In Aardvark Therapeutics Flagging Positive News - Yahoo Finance
Aardvark Therapeutics(AARD) Stock Options Chain | Quotes & News - Moomoo
AARD Stock Price, Quote & Chart | AARDVARK THERAPEUTICS INC (NASDAQ:AARD) - ChartMill
AARD Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Focuses on Pipeline ProgressAnalyst Drop Coverage - The Legal Advocate
AARD stock crashes 34% – here’s why this analyst finds it ‘hard to lean into’ Aardvark at this stage - MSN
Aardvark Therapeutics faces investigation after FDA halts its Phase 3 trial, causing stock to plunge. - Pluang
Aardvark Therapeutics shares plunge 56% after halting Phase 3 trial due to safety concerns. - Pluang
We're Keeping An Eye On Aardvark Therapeutics' (NASDAQ:AARD) Cash Burn Rate - Moomoo
FDA halts Aardvark Therapeutics rare disease study - MSN
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman - Barchart.com
FDA halts Aardvark Therapeutics' ARD-101 trial over heart safety concerns, stock now valued mainly for cash. - Pluang
Aardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path Forward (NASDAQ:AARD) - Seeking Alpha
AARD stock plummets after hours as cardiac safety concerns trigger FDA hold on late-stage program - MSN
FDA Clinical Hold, Competitive Pressure Drive Aardvark Therapeutics Downgrade as Price Target Slashed from $18 to $4 - TipRanks
Why Figma Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Sahm
Aardvark Therapeutics downgraded to Underperform from Buy at BofA - TipRanks
Under FDA Clinical Hold, Aardvark Therapeutics Seeks Path Forward for Metabolic Drug - MedCity News
Aardvark Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.3, Implies 187% Upside - TradingView
B. Riley Adjusts Aardvark Therapeutics Price Target to $7 From $8, Maintains Buy Rating - Moomoo
Aardvark plummets on FDA clinical hold on Prader-Willi Syndrome asset - Seeking Alpha
Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application - Moomoo
AARD Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
Aardvark Therapeutics Could Regain Investor Interest With Upcoming Results -- Market Talk - Moomoo
AARD Stock Crashes 34% – Here’s Why This Analyst Finds It ‘Hard To Lean Into’ Aardvark At This Stage - Stocktwits
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
FDA puts clinical hold on Aardvark’s IND - The Pharma Letter
Aardvark Therapeutics, Inc.Common Stock (Nasdaq:AARD) Stock Quote - The Chronicle-Journal
FDA Halts Aardvark Therapeutics Rare Disease Study - Benzinga
AARD Downgraded by Morgan Stanley -- Price Target Lowered to $3. - GuruFocus
FDA Places Full Hold On Aardvark’s ARD-101 Months After Voluntary Safety Pause - Citeline News & Insights
B. Riley Securities Maintains Aardvark Therapeutics(AARD.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
BTIG downgrades Aardvark Therapeutics stock rating on FDA hold By Investing.com - Investing.com Australia
Aardvark Therapeutics stock tumbles on FDA clinical hold, analyst downgrades - Investing.com Australia
2.60%
0.94%
자본화:
|
볼륨(24시간):